Mounjaro Half-Life and Pharmacokinetics, Straight From the FDA Label

This is a reference page. Its only job is to reproduce, accurately and with attribution, the pharmacokinetic statements in the FDA-approved United States prescribing information for Mounjaro, so somebody keeping a personal medication record can see the provenance of the numbers they meet elsewhere.

It is not medical advice. It has not been written or reviewed by a clinician, and it makes no recommendation about whether any medication is appropriate for anybody. It does not tell you how much to take, when to take it, or when to change anything. Those decisions belong to the person who prescribed your medication and who can see your individual circumstances.

If you want guidance rather than reference material, the right next step is your prescriber or pharmacist.

All figures on this page come from one document: MOUNJARO (tirzepatide) injection, for subcutaneous use — the United States Prescribing Information approved by the FDA. The pharmacokinetic statements sit in Section 12.3, Pharmacokinetics.

The copy consulted was read on DailyMed, the National Library of Medicine's mirror of current FDA-approved labeling, accessed 1 September 2026. The label records an Initial U.S. Approval of 2022, and Section 1 indicates Mounjaro as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.

Tirzepatide is also marketed under a second brand name with a different indication. The two labels are separate documents and they do not state identical pharmacokinetics in every respect, so this page quotes the Mounjaro label only; the Zepbound reference page quotes the other. Everything on this page is Mounjaro's own label.

Labels are revised, which is why the access date is printed beside each figure. If a number here ever conflicts with the current label, the current label wins.

Section 12.3 states a mean absolute bioavailability of 80% following subcutaneous administration.

Absolute bioavailability is the fraction of an administered dose that reaches systemic circulation unchanged, measured against an intravenous reference. Eighty percent is high and is characteristic of a subcutaneous peptide absorbed slowly and largely completely from the injection site.

The label adds a detail worth recording: similar exposure was achieved with administration in the abdomen, thigh or upper arm. That is a useful thing to know, because it separates two ideas that often get conflated. Rotating injection sites is generally advised for reasons relating to the tissue at the site; the label does not describe rotation as changing how much drug is absorbed.

The label states that following subcutaneous administration, the time to maximum plasma concentration of tirzepatide ranges from 8 to 72 hours.

That range deserves attention because it is remarkably wide — the upper bound is nine times the lower one. Reference tables routinely collapse it to a single figure, commonly 24 hours, and while that is a defensible working value it discards the most interesting thing the label says, which is how much the timing varies.

For somebody keeping records, the practical reading is this: if you are trying to associate how you felt at a particular moment with a peak concentration, the label does not support that level of precision. The window is too wide, and it is population data rather than a statement about you. Record what happened and when; leave the causal attribution to somebody qualified to make it.

Section 12.3 gives an elimination half-life of approximately 5 days, and the label connects that figure explicitly to the feasibility of once-weekly dosing. It also states that steady-state plasma tirzepatide concentrations were achieved following 4 weeks of once-weekly administration.

Put those together and the shape of the first month becomes clear. Because the dosing interval is longer than the half-life but not enormously longer, a meaningful proportion of each dose is still present when the next arrives. Levels therefore build across roughly the first four weeks before flattening.

This is the single most useful fact on the page for anybody keeping a record. What you experience in a given week is not a clean readout of the dose you took that week; it reflects an accumulated level that several previous weeks contributed to. A record spanning weeks is worth far more than a note about a single day.

Tirzepatide is escalated gradually rather than started at a maintenance level, and the prescribing information describes that escalation in its dosage and administration section.

This page does not reproduce it. Not because the information is hidden — it sits in a public document — but because a titration schedule is only meaningful attached to a specific person, and publishing one invites readers to follow it. Escalation timing is individualised constantly, for tolerability, for interactions, and for clinical circumstances no reference page can know about.

The framing this pillar uses throughout: a stepwise schedule exists, it is defined in the label, and it is applied to you by your prescriber. The job of a record — and of a tracking app — begins after that decision, when there is something real to write down.

GLP-1 Tracker treats a medication like Mounjaro as a record-keeping problem, which is the only kind of problem an app is qualified to solve here.

What it records is what you enter: the date of each dose you log, the injection site you noted, weight and BMI entries added over time, meals captured through the photo scan with calories, protein and fiber estimated, and any notes about how a week went. It holds those together in one timeline rather than scattered across a notes app, a paper diary and memory.

What it does not do is decide anything. It does not evaluate whether your routine is working, it does not flag anything as clinically significant, and it does not generate schedules. The value is entirely in having an accurate record when somebody qualified asks what has been happening.

GLP-1 Tracker includes an educational medication-level view that draws a curve from the doses you have logged and a published half-life figure of the kind quoted on this page.

It is a teaching illustration and nothing more. It is built from population-level label figures, not from you. It cannot account for your body weight, your kidney function, injection-site variation, adherence gaps, or the ordinary biological variability between two people given identical doses — and with a labeled time-to-peak window as wide as 8 to 72 hours, the variability being averaged away is substantial.

The legitimate use is intuition: seeing why a weekly medication accumulates over the first month, or why a missed dose does not produce an immediate cliff. The illegitimate use is treating it as information about your own body, or letting it influence a dose.